# OnCo record leap-012 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/leap-012/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "leap-012", "NCT04246177" ;
  schema:name "LEAP-012"@en ;
  schema:description "Adding lenvatinib and pembrolizumab to TACE delayed progression by four and a half months but did not help patients live longer."@en ;
  schema:url <https://onco.cc/trials/leap-012/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04246177>, <https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)02575-3/abstract> ;
  onco:status "mixed" ;
  onco:tag "lesson:surrogate-endpoint" ;
  onco:phase "3" ;
  schema:startDate "2020-05-22" ;
  onco:cancers <https://onco.cc/cancers/hcc/>, <https://onco.cc/cancers/hcc-intermediate/> ;
  onco:technologies <https://onco.cc/technologies/tace/> ;
  onco:drugs <https://onco.cc/drugs/lenvatinib/>, <https://onco.cc/drugs/pembrolizumab/> ;
  onco:companies <https://onco.cc/companies/eisai/> .